Copyright 2017 American Medical Association. All Rights Reserved.
The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.
Ocular surface inflammation leading to dry eyes can be caused by altered tear-film composition, reduced tear production, poor lid function, environmental conditions, or diseases such as Sjögren’s syndrome. Anticholinergic drugs, estrogens, and selective serotonin reuptake inhibitors (SSRIs) can also cause dry eyes. Older age and female sex are risk factors.
Lifitegrast (Xiidra) for Dry Eye Disease. JAMA. 2017;317(14):1473–1474. doi:10.1001/jama.2016.12872
Customize your JAMA Network experience by selecting one or more topics from the list below.